普萘洛尔治疗婴幼儿血管瘤的共识声明。
Consensus statement for the treatment of infantile haemangiomas with propranolol.
作者信息
Smithson Sarah L, Rademaker Marius, Adams Susan, Bade Stuart, Bekhor Philip, Davidson Samantha, Dore Amanda, Drummond Catherine, Fischer Gayle, Gin Alexander, Grills Claire, Halbert Anne, Lokmic Zerina, McCahon Emma, Morgan Vanessa A, Murrell Dedee F, Orchard David, Penington Anthony, Purvis Diana, Relic John, Robertson Susan, Robinson Aaron J, Scardamaglia Laura, Su John, Tan Swee, Wargon Orli, Warren Lachlan, Wong Li-Chuen, Zappala Tania, Phillips Roderic
机构信息
Royal Children's Hospital, Melbourne, Victoria, Australia.
Waikato Hospital, Hamilton, New Zealand.
出版信息
Australas J Dermatol. 2017 May;58(2):155-159. doi: 10.1111/ajd.12600. Epub 2017 Mar 1.
Although most infantile haemangiomas do not require treatment due to a natural history of spontaneous involution, some require early intervention. The Australasian Vascular Anomalies Network and the Australasian Paediatric Dermatology Network have developed a consensus statement for the treatment of infantile haemangiomas with oral propranolol. Infants with haemangiomas that are life threatening, at risk of ulceration, or at risk of causing a significant functional impairment, psychological impact or physical deformity should be treated early with oral propranolol. Oral propranolol is safe and effective and in most healthy infants oral propranolol can be started in an outpatient setting.
尽管大多数婴儿血管瘤由于其自然消退的病程而无需治疗，但有些则需要早期干预。澳大拉西亚血管异常网络和澳大拉西亚儿科皮肤病学网络已制定了关于口服普萘洛尔治疗婴儿血管瘤的共识声明。患有危及生命、有溃疡风险、或有导致严重功能障碍、心理影响或身体畸形风险的血管瘤婴儿，应尽早用口服普萘洛尔治疗。口服普萘洛尔安全有效，在大多数健康婴儿中，口服普萘洛尔可在门诊开始使用。
Zotero 插件